Start: December 2015
End: December 2018
What Is This Study About?
This study will test two different drugs, alone and in combination, to assess their effect on cognitive function in people with HIV as they age. The study will help researchers learn about the contribution of the neuronal cholingeric receptor system to cognitive impairment in this population.
Do I Qualify To Participate in This Study?
- HIV-positive for at least 5 years (on antiretroviral therapy for at least 6 months with a recent viral load, within 6 months, of less than 50 and CD4 count of more than 200) or HIV-negative, at-risk individuals
- Negative urine pregnancy test
- Adequate visual and auditory ability to complete neuropsychological testing
Must NOT have:
- Unmanaged HIV Infection, identified by no current medication regimen or the presence of one or more AIDS-defining conditions
- Antiretroviral regimen that includes a protease inhibitor medication
- History of heart disease or abnormal electrocardiograph at screening
- Heavy use of nicotine
- Current alcohol or substance abuse
- Current use of antipsychotics, benzodiazepines, or other psychoactive medications
- Psychiatric disorder
- Heart attack in the past year or unstable or severe cardiovascular disease
If I Qualify, Who Do I Contact?
Contact study personnel listed either under the general study contact or the location nearest you.
Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.
Where Is This Study Located?
Lead: Vanderbilt University Medical Center
Source: ClinicalTrials.gov ID: NCT03244488